Navigation Links
HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
Date:11/3/2010

ghtened engineering, testing, document and related preparation costs associated with the planned bridge-to-transplant premarket approval application (PMA) submission to the FDA, together with increased expenditure on the Company's pipeline technologies.  Selling, general and administrative expenses were $7.0 million in the third quarter of 2010, with non-cash, share-based compensation charges contributing $1.8 million.  For the first nine months of 2010, total operating expenses were $40.8 million compared to $21.7 million for the same period of 2009.  The increases described above also reflect ongoing expansion of commercialization activities in Europe and other countries outside the U.S., additional investment in HeartWare's technology pipeline and increased recruitment for key positions to meet expected rising demand for the Company's products and the need to support clinicians in a larger number of centers.

Net loss for the third quarter of 2010 was $7.8 million, or a $0.57 loss per basic and diluted share, compared to a $5.9 million net loss, or a loss of $0.60 per basic and diluted share, in the third quarter of 2009.  For the nine months ended September 30, 2010, the Company recorded a net loss of $22.4 million, or a $1.66 loss per basic and diluted share, compared to a $19.0 million net loss, or a loss of $2.07 per basic and diluted share, in the first nine months of 2009.

"Today, nearly 700 advanced heart failure patients globally have received the HVAD® pump," added Mr. Godshall.  "Our current priorities include: preparation for the presentation of data from our U.S. bridge-to-transplant (BTT) study at the American Heart Association Scientific Sessions on November 14; compilation of preclinical, manufacturing and clinical data into a PMA submission to the FDA for BTT, which is targeted for year-end; initiation of all 50 sites in our destination therapy trial; and preparing the MVAD portfolio for Good Laboratory P
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. HeartWare to Report Financial Results for Third Quarter of 2010
2. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
3. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
4. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
5. HeartWare International Reports Third Quarter Revenues of $7.5 Million
6. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
7. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
8. Presentation of HeartWare Clinical Results
9. Saudi Arabias King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy
10. International Isotopes Inc. Announces Completion of a $5.8 Million Private Placement
11. Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... BOCA RATON, Fla. , Nov. 25, 2014 ... has entered into a multi-product ANDA agreement with ... Maryland ) under which Breckenridge and Pii ...  Under the terms of the agreement, Pii will ... will market and distribute the products under its ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... 1 Older adults who exercise regularly show increased cerebral blood flow ... to findings presented today at the annual meeting of the Radiological Society ... The study, conducted at the University of North Carolina ( ... of older adults who exercise to brain scans of those who do ...
... New study finds the majority of acute lymphoblastic leukemia relapse ... of diagnosis , , MEMPHIS, ... Hospital have identified distinctive genetic changes in the cancer cells ... The finding offers a pathway to designing treatments for ALL ...
Cached Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3
(Date:11/27/2014)... Luciana Lagana and her husband ... Omadox, a feature film that received 9 awards at the ... ensemble cast. It is also an official selection of the ... a successful cinematic career for James Noel, a young filmmaker ... enjoy experimental mystery, filmed in glorious black and white, watching ...
(Date:11/27/2014)... 27, 2014 Blood-borne pathogens raise the ... precautions and procedures in place to counter this. However, ... of things tainted with menstrual blood are taken as ... simpler, more sanitary way to handle tampons and menstrual ... from Sonora, Calif. , He then created a prototype ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... By Dennis Thompson ... -- An experimental Ebola vaccine appears to be safe and ... the deadly virus, according to early clinical trial results reported ... of the phase I clinical trial for the vaccine paves ... nations of Liberia and Sierra Leone as early as January, ...
(Date:11/27/2014)... The founders of VIM & VIGR, a ... functioning compression socks, are proud to announce the debut of ... Gradient Pressure (TM) knitting technology that is designed to increase ... commitment to adding flair and style to a product that ... the eye of a writer at The New York ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... Sciences Corporation announced,today a new initiative that ... instruments used in medical practice and healthcare,2.0 ... draws upon the,cognitive and anthropologic sciences, is ... human intelligence,s reliance on,narrative for richly conveying ...
... Build Healthy Communities, VICTORVILLE, Calif., April 16 ... Victorville Earth Day Eco Tote giveaway.,On Tuesday, April ... will be handing out recyclable Eco Totes to ... Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical Group ...
... have discovered sleep patterns in a type of anesthesia ... snooze. , The anesthetic used in the study, known ... tool to more thoroughly investigate ways of treating sleep ... one of the studys co-authors and an associate professor ...
... AFL ) announced today that it will ... on April 23, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO ... release, Aflac Incorporated will,webcast a conference call scheduled ... the teleconference, Aflac Incorporated Chairman and CEO Dan ...
... middle could be making us hungrier, so we eat more, ... Dr. Yaiping Yang and his colleagues at the Lawson Health ... abdominal fat tissue can reproduce a hormone that stimulates fat ... in the way we think about and treat abdominal obesity. ...
... Management Program improves patient care while ... saving ... of its inaugural Best Practices in Consumer Empowerment and,Protection Awards ... NeuroScience, Inc. and Eli Lilly,and Company as Silver Award winners ...
Cached Medicine News:Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 2Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 3Health News:Aflac Incorporated To Release First Quarter Results on April 23, 2008 2Health News:Your belly fat could be making you hungrier 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 4